A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-20 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Duarte and his friend Brozin, the founders of the first Nando's, bought a restaurant previously called "Chickenland" and renamed it Nando's. They opened it in 1987. By 2018, there were 340 Nando's restaurants throughout its home market of South Africa.
Dr. Stone is an anime television series produced by TMS Entertainment based on the manga series of the same name written by Riichiro Inagaki and illustrated by Boichi. Set 3,700 years after a mysterious light turns every human on the planet into stone, genius boy Senku Ishigami emerges from his petrification into a "Stone World" and seeks to rebuild human civilization from the ground up. Dr. Stone's second season, titled Dr. Stone: Stone Wars, aired from January 14 to March 25, 2021. The season premiered on Tokyo MX and KBS in a dual simulcast, with other networks following at later timeslots. It focuses on the story of the "Stone Wars" arc from the manga, in which Senku and the Ishigami villagers of the Kingdom of Science go to war with Tsukusa's Kingdom of Strength. The season is streamed by Crunchyroll worldwide outside of Asia, while then-separate company Funimation produced a simuldub. The season ran for 11 episodes. A sequel was announced after second season finale. The English dub for Stone Wars aired on Adult Swim's Toonami programming block from May 16 to July 25, 2021. The opening theme song is "Rakuen" (楽園; lit. 'Paradise') performed by Fujifabric, while the ending theme song is "Koe?" (声?; lit. 'Voice?') performed by Hatena.
A study that compares two groups of people: those with the disease or condition under study (cases) and a very similar group of people who do not have the disease or condition (controls). Researchers study the medical and lifestyle histories of the people in each group to learn what factors may be associated with the disease or condition. For example, one group may have been exposed to a particular substance that the other was not. Also called a retrospective study. (NCI) Clinical
The general law of tort may also provide remedies where an employer's breach of the duty of care results in particular harm, such as psychiatric injury. In Naidu v Group 4 Securitas Pty Ltd Mr Naidu, while working as a security guard through labour hire firm ISS Security at Nationwide News, was subjected to racial abuse, physical assault, threats to be fired and never work again, and making Mr Naidu work for free at the home of the abusive supervisor, Mr Chaloner. He was psychologically scarred, without a job and his marriage broke down as a result. On appeal, the NSW court upheld damages against Nationwide News of $1,767,050, but rejected damages against ISS on the basis that there was not a "reasonably foreseeable risk of cognisable psychiatric harm to the plaintiff", even though ISS was benefitting from Mr Naidu's labour as much as Nationwide News. Because the wider issue of bullying is a general problem, in 2013 the Fair Work Act 2009 Part 6-4B was added to prohibit being "bullied at work". This means repeated and unreasonable behaviour that creates a risk to health and safety.
Sources: en.wikipedia.org
The album was originally scheduled for worldwide release in 2017, but was postponed in lieu of Live in Chicago; however, it was only released in Japan in September 2017, with a bonus disc with recordings from the band's tour there in December 2015. The worldwide release added a performance of "Fracture", plus three pieces drawn from the nightly Fripp-composed introductory soundscapes with improvisations by Collins and Levin: these pieces were arranged and realised by David Singleton, reflecting similar work he'd performed for Thrakattak twenty years earlier. On 20 October 2018, a further live album/video was released, Meltdown: Live in Mexico City, recorded during dates in July 2017.
But, unquestionably, the feature of Compo rations destined to be remembered beyond all others is Compo tea...Directions say to "sprinkle powder on heated water and bring to the boil, stirring well, three heaped teaspoons to one pint of water." Every possible variation in the preparation of this tea was tried, but...it always ended up the same way. While still too hot to drink, it is a good-looking cup of strong tea. Even when it becomes just cool enough to be sipped gingerly, it is still a good-tasting cup of tea, if you like your tea strong and sweet. But let it cool enough to be quaffed and enjoyed, and your lips will be coated with a sticky scum that forms across the surface, which if left undisturbed will become a leathery membrane that can be wound around your finger and flipped away...
2 parts bai zhi (Chinese:白芷，Angelica dahurica); 2 parts cao wu (Chinese:草烏，Aconitum sp., monkshood or wolfsbane); 2 parts chuān ban xia (Pinellia ternata); 2 parts chuān xiōng (Ligusticum wallichii, Cnidium rhizome, Cnidium officinale or Szechuan lovage); 2 parts dong quai (Angelica sinensis or female ginseng); 1 part tian nan xing (Arisaema rhizomatum or cobra lily) 8 parts yang jin hua (Datura stramonium, Korean morning glory, thorn apple, jimson weed, devil's trumpet, stinkweed, or locoweed). The active ingredients in tsūsensan are scopolamine, hyoscyamine, atropine, aconitine and angelicotoxin. When consumed in sufficient quantity, tsūsensan produces a state of general anesthesia and skeletal muscle paralysis. Shutei Nakagawa (1773–1850), a close friend of Hanaoka, wrote a small pamphlet titled "Mayaku-ko" ("narcotic powder") in 1796. Although the original manuscript was lost in a fire in 1867, this brochure described the current state of Hanaoka's research on general anesthesia. On 13 October 1804, Hanaoka performed a partial mastectomy for breast cancer on a 60-year-old woman named Kan Aiya, using tsūsensan as a general anaesthetic. This is generally regarded today as the first reliable documentation of an operation to be performed under general anesthesia. Hanaoka went on to perform many operations using tsūsensan, including resection of malignant tumors, extraction of bladder stones, and extremity amputations. Before his death in 1835, Hanaoka performed more than 150 operations for breast cancer.
Sources: en.wikipedia.org
According to the Chinese chronicles of the Jin dynasty (265-316 CE), there were already a thousand Buddhist stupas and temples in Kucha by the 3rd century CE. The earliest painted caves at Kizil are thought to be Cave of the Hippocampi (Cave 118) and Treasure Caves C and B (Caves 83 and 84 respectively). Cave 118, possibly the earliest of the three, is located deep inside the central valley. Cave 83 and 84 are located at the entrance of the same valley. These caves have simple architectural structures, together with paintings in a clear style, reflecting Indian influences. Noble or wealthy Tocharian donors from Kucha, wearing tunics, sometimes appear kneeling at the side of devotional paintings.
== Critical reception == Gordon Freeman quickly became and then remained one of the most popular video game characters ever. In 2008, The Age ranked him as the 16th-best Xbox character of all time, adding that "no one has done more for the reputations and street cred of theoretical physicists than Valve." In 2009, GameDaily listed the "strong and silent type" in their top 25 video game archetypes, using Gordon Freeman as an example. In 2010, Empire ranked him as the number one Greatest Video Game Character, commenting that "the character is the quintessential geek fantasy" who "has become a gaming icon, synonymous with the apotheosis of first-person action." He was also ranked 14th on UGO.com's list of top 100 heroes in all media, with a comment that "an MIT graduate, donning black-framed glasses and a goatee, he's not the guy you'd picture decimating the alien threat." In 2012, GamesRadar ranked him as the sixth "most memorable, influential, and badass" protagonist in games, adding: "It's how the characters of the Half-Life universe treat Gordon Freeman, not the way he treats them, that shape such a compelling character." In 2013, Complex ranked him as the 45th "most badass" video game character of all time. In 1998, readers of GameSpot ranked him as the fifth-best Hero of gaming. In 2009, a public poll on GameSpot resulted in him being voted the All Time Greatest Video Game Hero. He was also voted as the eighth-best video game character of all time in the Guinness World Records Gamer's Edition 2011.
She had been born and brought up in Llangadog, as had her father, who is thought to be "Grandpa" in Thomas's short story A Visit to Grandpa's, in which Grandpa expresses his determination to be buried not in Llansteffan but in Llangadog. Evan worked on the railways and was known as Thomas the Guard. His family had originated in another part of Welsh-speaking Carmarthenshire, in the farms that lay around the villages of Brechfa, Abergorlech, Gwernogle and Llanybydder, and which the young Thomas occasionally visited with his father. His father's side of the family also provided the young Thomas with another kind of experience; many lived in the towns of the South Wales industrial belt, including Port Talbot, Pontarddulais and Cross Hands. Thomas had bronchitis and asthma in childhood and struggled with these throughout his life. He was indulged by his mother, Florence, and enjoyed being mollycoddled, a trait he carried into adulthood, becoming skilled in gaining attention and sympathy. But Florence would have known that child deaths had been a recurring event in the family's history, and it is said that she herself had lost a child soon after her marriage. If Thomas was protected and spoiled at home, however, the real spoilers were his many aunts and older cousins, those in both Swansea and the Llansteffan countryside. Some of them played an important part in both his upbringing and his later life, as Thomas's wife, Caitlin, has observed: "He couldn't stand their company for more than five minutes... Yet Dylan couldn't break away from them, either.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.